Results 11 to 20 of about 965,759 (306)

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration [PDF]

, 2005
Background The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate.Methods and ...
Wynhoven, B, Cane, P, Holguin, A, Pedro Cahn, Maria Belen Bouzas, Africa Holguin, Luis F Brigido, Sirivichayakul, S, Anne-Mieke Vandamme, Camacho, R, Efron, B, Koya Ariyoshi, Grossman, Z, Robert W Shafer, Shafer, RW, Bouzas, MB, Brian Wynhoven, Ricardo Camacho, Jonathan N Weber, Harrigan, PR, Ariyoshi, K, Ana Patricia Carvalho, Rosangela Rodrigues, Rudich, H, Candice Pillay, Soares, MA, Katzenstein, DA, Vandamme, AM, Clarke, J, Lynn Morris, Snoeck, J, Soriano, V, Rodrigues, R, Brigido, LF, Wataru Sugiura, Praphan Phanuphak, Kantor, R, Sugiura, W, John Clarke, Jonathan M Schapiro, Rami Kantor, David A Katzenstein, Carvalho, AP, P Richard Harrigan, Patricia Cane, Phanuphak, P, Brad Efron, Pillay, D, Pillay, C, Sunee Sirivichayakul, Joke Snoeck, Cahn, P, Hagit Rudich, Schapiro, JM, Morris, L, Zehava Grossman, Amilcar Tanuri, Tanuri, A, Weber, JN, Vincent Soriano, Deenan Pillay, Marcelo A Soares, Lynn Morris (7883), Brigido Luis F, Amilcar Tanuri (7885), Praphan Phanuphak (7886), Phanuphak Praphan, Ana Patricia Carvalho (7866), Camacho Ricardo, Soriano Vincent, Weber Jonathan N, Snoeck Joke, Maria Belen Bouzas (7878), Rudich Hagit, Sugiura Wataru, Rodrigues Rosangela, Hagit Rudich (7874), Pillay Deenan, Deenan Pillay (7888), Morris Lynn, Pillay Candice, Pedro Cahn (4922), Harrigan P. Richard, Anne-Mieke Vandamme (7884), Candice Pillay (7873), Robert W Shafer (7892), John Clarke (7869), Sunee Sirivichayakul (7870), Efron Brad, Kantor Rami, Rami Kantor (7863), Brad Efron (7865), Carvalho Ana Patricia, Holguin Africa, Cahn Pedro, Tanuri Amilcar, Ariyoshi Koya, Vandamme Anne-Mieke, Brian Wynhoven (7867), Sirivichayakul Sunee, Wataru Sugiura (7879), P. Richard Harrigan (7889), David A Katzenstein (7864), Joke Snoeck (7872), Africa Holguin (7876), Katzenstein David A, Koya Ariyoshi (7877), Vincent Soriano (7880), Shafer Robert W, Luis F Brigido (7881), Soares Marcelo A, Patricia Cane (7868), Rosangela Rodrigues (7875), Bouzas Maria Belen, Grossman Zehava, Schapiro Jonathan M, Marcelo A Soares (7871), Zehava Grossman (7882), Cane Patricia, Jonathan N Weber (7887), Clarke John, Wynhoven Brian, Jonathan M Schapiro (7891), Ricardo Camacho (7890)   +123 more
core   +2 more sources

Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study

Antiviral Therapy, 2022
Background In the DAWNING study, dolutegravir + 2 nucleoside reverse transcriptase inhibitors (NRTIs) demonstrated superior efficacy at Week 48 and a favourable safety profile compared with lopinavir/ritonavir + 2 NRTIs in adults with HIV-1 failing first-
Dannae Brown, Richard Kaplan, Marcelo Losso, Carlos Brites, Ruolan Wang, Mark Underwood, Judy Hopking, Michael Aboud, Jörg Sievers   +8 more
doaj   +1 more source

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

Frontiers in Virology, 2022
The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Richa Dwivedi, Youya Wang, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose   +4 more
doaj   +1 more source

In silico prediction of telomerase reverse transcriptase inhibitors using modified retinol for the treatment of arsenical cancer

Bangabandhu Sheikh Mujib Medical University Journal, 2016
Retinol molecule was modified to predict the inhibitors of telomerase reverse transcriptase for the treatment of arsenical cancer through in silico study. Telomerase activity is expressed in the cancerous conditions which can be the target for anticancer
Kipchu Tshering, Mir Misbahuddin
doaj   +1 more source

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

PLoS ONE, 2020
BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin, Christina Ludema, Stephen R Cole, Carol E Golin, William C Miller, Meredith G Warshaw, Ross E McKinney, PENPACT-1 (PENTA 9 / PACTG 390) Study Team   +7 more
doaj   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A., K. Mataruka, B. Kikaire, M. Nabankkema, H. Grosskurth, P. Khauka, M. Namyalo, C. Kityo, C. Parry, C. F. Gilks, M. Spyer, R. Magala, P. Kaleebu, R. L. Goodall, P. Nkurunziza, N. Ndembi, R. Goodall, A. Zalwango, T. Pattery, L. Generous, P. Awio, D. Dunn, D. Pillay, K. Fadhiru, G. Kabuye, L. Mugarura, G. Nassuna, M. Chirara, M. Katuramur, B. Magambo, J. Nkalubo, R. Massa, A. van Cauwenberge, E. Zalwango, V. Robertson, P. Munderi, D. Yirrell, R. Kasirye, D. M. Gibb, A. Kapaata, D. T. Dunn, D. Nsibambi, F. Lyagoba, T. Musunga, A.L. McCormick, M. Nakazibwe, C. Gilks   +70 more
core   +1 more source

Normal and Tumour Tissue mRNA Expressions of Telomerase Complex Genes in Several Types of Cancer

Balkan Medical Journal, 2017
Aims: To investigate the changes in mRNA expression levels of telomerase-related significant proteins in several types of cancer. Methods: Human telomerase reverse transcriptase, pontin, reptin and dyskerin expressions were measured in normal and tumour
Emel Çalışkan Can, M. Can Atalay, Ece Miser Salihoğlu, Ülkü Yalçıntaş Arslan, H. Bolkan Şimşek, Sevgi Yardım Akaydın   +5 more
doaj   +1 more source

Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [PDF]

Journal of Advanced Pharmacy Research
Objectives: The nucleic acid-binding cleft in HIV-1 reverse transcriptase (HIV-1 RT) is essential because of its interactions with the polymerase and RNase H active sites. Studying its binding sites for nucleoside reverse transcriptase inhibitors (NRTIs)
Roohallah Yousefi
doaj   +1 more source

Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites [PDF]

, 2000
Recently, significant numbers of individuals with primary human immunodeficiency virus (HN) infection have been found to harbor viral strains with reduced susceptibility to antiretroviral drugs.
Jeannette M. Whitcomb, Susan J. Little, Philip H. Keiser, Hellmann, N S, Connick, E, D'Aquila, R T, Elizabeth Connick, Douglas D. Richman, Christos J. Petropoulos, Richard T. D'Aquila, Whitcomb, J M, Joseph K. Wong, Keiser, P H, Brown, A J, Wong, J K, Richman, D D, Heather M. Precious, Eric S. Daar, Huang, W, Wei Huang, Precious, H M, Nicholas S. Hellmann, Marlynne Quigg, Quigg, M, Daar, E S, Little, S J, Andrew J. Leigh Brown, Petropoulos, C J   +27 more
core   +1 more source

Experience With Pretravel Testing for SARS-CoV-2 at an Academic Medical Center

Academic Pathology, 2021
International travel has been a significant factor in the coronavirus disease 2019 pandemic. Many countries and airlines have implemented travel restrictions to limit the spread of the causative agent, severe acute respiratory syndrome coronavirus-2.
Katherine L. Imborek MD, Matthew D. Krasowski MD, PhD, Paul Natvig MD, Anna E. Merrill PhD, Daniel J. Diekema MD, Bradley A. Ford MD, PhD   +5 more
doaj   +1 more source